AIDS

AHF Protests USPS Refusal to Deliver SRO Tenants’ Mail

Retrieved on: 
Tuesday, March 5, 2024
Legal, Advocacy Group Opinion, Public Policy, Government, Professional Services, AIDS, White House, Federal Government, Health, State, Local, HHR, AIDS Healthcare Foundation, USPS, HHF, Skid row, AHF, Housing, The Postal Service, Tenant, Homelessness, Human, Louis DeJoy, SRO

AHF complied with the law and installed USPS-approved mailboxes for all the tenants at the SRO buildings that AHF owns and operates.

Key Points: 
  • AHF complied with the law and installed USPS-approved mailboxes for all the tenants at the SRO buildings that AHF owns and operates.
  • For several years and on many occasions, AHF informally asked the USPS to deliver mail properly to its Skid Row properties and even filed a formal administrative claim with the USPS to get a change in delivery to no avail.
  • In 2017, under its Healthy Housing Foundation division, AHF began purchasing and repurposing SRO hotels to address the escalating homelessness and affordable housing crises.
  • Today, AHF provides more that 1,400 SRO housing units as primary and permanent residences to low-income tenants in 13 multi-unit SRO buildings across Greater Los Angeles.

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Retrieved on: 
Tuesday, March 5, 2024
AIDS, Health, Infectious Diseases, Hospitals, Research, Science, Biotechnology, Infection, BCG, Medicine, MD, FDA, Safety, Hook effect, NMIBC, Rockefeller University, University, ART, Patient, Journal, NK, Management of HIV/AIDS, HIV/AIDS, HIV, Viral load, Immune system, Vaccine

ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.

Key Points: 
  • ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.
  • All participants in this Phase 1 study experienced significant reduction in infection levels following treatment with N-803.
  • HIV can disable NK cells—a frontline defense against viral infections—making it difficult to clear the infection.
  • The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells.

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

Retrieved on: 
Wednesday, March 6, 2024
Research, Infectious Diseases, Finance, Clinical Trials, Professional Services, Biotechnology, AIDS, Pharmaceutical, Health, Science, Infection, Bangladesh Technical Education Board, HIV/AIDS, RAMS, Janssen Pharmaceuticals, Failure, Aes, Rilpivirine, Fungal infection, GSK, NIAID, CROI, Research and development, Arm, ISR, Life, ACTG, Data monitoring committee, Pfizer, Johnson & Johnson, Partner (business rank), Conference, ART, History, MPH, Male, ViiV Healthcare, DSMB, Mental health, HIV, SOC, Viral load, VF, Vaccine

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.

Key Points: 
  • Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare, said: “It’s estimated that one-third of people living with HIV in the United States struggle with maintaining viral suppression.
  • Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression.
  • 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75% CI–29.8%, -0.8%)}.
  • Three participants in the LA-ART arm had serious injection site reactions (ISR) and one participant discontinued due to an ISR.

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, MSD, MRK, Week, Doctor of Philosophy, Gilead Sciences, Fungal infection, CROI, Islatravir, MD, AIDS, Science, Boxed warning, Female, Nausea, Conference, European, Safety, Stigma, Lenacapavir, Tablet, HIV, Viral load, Xerostomia, Merck & Co., Pharmaceutical industry

These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).

Key Points: 
  • These late-breaking data were presented during an oral session at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ).
  • At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA
  • The potent antiviral activities, along with pharmacokinetic profiles of islatravir and lenacapavir, support their development as an investigational once-weekly oral combination regimen.
  • No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24.

Nation’s First Transgender Facility Vote Center Celebrates Election Day

Retrieved on: 
Monday, March 4, 2024
Advocacy Group Opinion, Elections, Campaigns, LGBTQ+, Public Policy, Government, Philanthropy, AIDS, State, Local, Consumer, Health, Foundation, Transgender, Connie Norman

The Connie Norman Transgender Empowerment Center (CONOTEC), a facility providing comprehensive resources, training, support, and medical services for Transgender people living in Los Angeles, will be open to press for primary election day coverage as the nation’s first-ever Transgender facility to serve as a Vote Center.

Key Points: 
  • The Connie Norman Transgender Empowerment Center (CONOTEC), a facility providing comprehensive resources, training, support, and medical services for Transgender people living in Los Angeles, will be open to press for primary election day coverage as the nation’s first-ever Transgender facility to serve as a Vote Center.
  • CONOTEC has been open to Los Angeles County voters since March 2, 2024, and voting on primary day will run from 7:00 am to 8:00 pm.
  • Beginning at 12:00 pm, the center will have a DJ, refreshments, and a “red carpet” photo booth on site to mark the center making history.
  • Lt.

ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, FDA, AIDS, Health, Training, Pharmaceutical, Other Education, Other Philanthropy, Philanthropy, Research, Infectious Diseases, Education, Science, Clinical Trials, Acquisition, Pre-exposure prophylaxis, Pfizer, Incidence, Shionogi, Woman, Medicine, Fungal infection, GSK, CROI, HIV Medicine, Notifiable disease, Emergency medicine, Dawn, Conference, Gynaecology, Mentorship, Preceptor, Patient, MPH, ViiV Healthcare, HIV, Obstetrics, American Academy, Pharmaceutical industry

Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.

Key Points: 
  • Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.
  • Dawn K. Smith HIV Prevention Clinical Fellowship.
  • The fellowship will provide comprehensive HIV training to non-infectious disease clinicians serving communities disproportionately affected by HIV.
  • Dawn K. Smith HIV Prevention Clinical Fellowship, experienced HIV clinicians will provide that training in priority populations and areas, with a special emphasis on pre-exposure prophylaxis (PrEP).”
    The Dr.

Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, AIDS, General Health, Health, Infectious Diseases, Hospitals, Clinical Trials, Bictegravir, ARV, CD4, Week, Doctor of Philosophy, Aes, Gilead Sciences, Fungal infection, Research, CROI, MDR, MD, Diarrhea, Science, Food, Female, Hook effect, ZAB, Conference, Constipation, European, Safety, Group 2, Black, Lancet, COVID-19, RNA, Public, Patient, Lenacapavir, Plasma, TAB, Observational study, HIV, Viral load

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
  • “The latest findings across our HIV pipeline showcase the potential of multiple candidates to help transform HIV management,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences.
  • It is estimated that up to 10% of people with HIV take a complex treatment regimen, defined as 2 or more pills each day.
  • Results showed that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study.

AHF Urges WHO: Save Critical HIV Tech

Retrieved on: 
Monday, March 4, 2024
Research, General Health, Medical Devices, Healthcare Reform, Infectious Diseases, Public Policy, Advocacy Group Opinion, Health Technology, Science, Biotechnology, AIDS, Health, Government, CD4, AIDS Healthcare Foundation, POC, AHF, BD (company), World Health Organization, Abbott Laboratories, Patient, Diagnosis, WHO, HIV, Viral load, Wind, Immune system

AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.

Key Points: 
  • AIDS Healthcare Foundation (AHF) urges the World Health Organization (WHO) to call on manufacturers of vital point-of-care (POC) CD4 equipment, including Abbott Laboratories and Becton Dickinson (BD), to continue production of the HIV testing equipment and any necessary commodities that ensure proper functioning.
  • “Working in 46 countries, AHF country teams are seeing the consequences of Abbott’s and BD’s decisions firsthand, particularly in Africa and Asia.
  • CD4 testing shows how HIV damages our immune system since the virus targets and destroys CD4 cells.
  • While CD4 count is not vital for HIV diagnosis, it’s extremely important upon diagnosis, as the patient’s condition may have already progressed to AIDS—thus essential to the HIV continuum of care.

AHF Opens Food Pantry for San Diego Veterans

Retrieved on: 
Friday, March 1, 2024
Philanthropy, State, Local, Defense, Food, Beverage, Advocacy Group Opinion, Foundation, Retail, AIDS, Other Philanthropy, Military, Health, Public Policy, Government, Veterans, Research, AIDS Healthcare Foundation, Fortnight, AHF, Safety, Veteran, Veterans of Foreign Wars, Farm

Food for Health , a program under the AIDS Healthcare Foundation (AHF), is launching the Heroes Pantry in San Diego this weekend to alleviate the burden of food insecurity among veterans, active duty servicemembers, and military families exacerbated by the high cost of living, especially for those facing health challenges or needing to cover medical expenses.

Key Points: 
  • Food for Health , a program under the AIDS Healthcare Foundation (AHF), is launching the Heroes Pantry in San Diego this weekend to alleviate the burden of food insecurity among veterans, active duty servicemembers, and military families exacerbated by the high cost of living, especially for those facing health challenges or needing to cover medical expenses.
  • The new Heroes Pantry will offer fresh vegetables and fruits sourced directly from farms, with a focus on providing healthy options tailored to veterans with specific dietary needs.
  • RAND reports that 1.4 million veterans struggle to access adequate food, leading to severe health implications.
  • "Veterans should not be forced to choose between basic necessities like rent and food,” added Wendy Calderon, VFW Post Commander.

The Food Network New York City Wine & Food Festival Announces Move to Brooklyn with Sprawling 450,000 Square Foot Culinary Campus

Retrieved on: 
Thursday, February 29, 2024
Food, Beverage, Women, Retail, Other Philanthropy, Men, Other Entertainment, TV and Radio, Family, Consumer, Fund Raising, Philanthropy, LGBTQ+, Entertainment, Restaurant, Bar, Wine & Spirits, Events, Concerts, General Entertainment, Supermarket, Celebrity, Love, Food Network, Wine, New Yorker, Caregiver, Education, FEED, AIDS, Festival, Volunteering, NYC Ferry, Health, Brooklyn Army Terminal, Senior counsel, EAT, Sweet Sixteen, Film industry

The Food Network New York City Wine & Food Festival (NYCWFF) today shares its 2024 return, debuting a move to a new 450,000 square foot culinary campus at Brooklyn Army Terminal in Sunset Park.

Key Points: 
  • The Food Network New York City Wine & Food Festival (NYCWFF) today shares its 2024 return, debuting a move to a new 450,000 square foot culinary campus at Brooklyn Army Terminal in Sunset Park.
  • “We’re incredibly excited to expand our footprint to Brooklyn and offer our most attended events at one culinary campus.
  • The Food Network New York City Wine & Food Festival is hosted by God’s Love We Deliver with 100% of the Festival’s net proceeds supporting New Yorkers facing severe illness.
  • In November 2022, BizBash named the Festival the #1 Food & Restaurant Industry event in New York for the 10th year in a row.